Lun - Ven 8:00 - 17:00
Expiry of patents leading to launch of
The generics segment accounts for the largest market share due to patent expiration of branded drugs and increasing demand for low-cost generics globally. Generics are expected to witness significant growth over the forecast period. North America is expected to be the largest market for sildenafil drug market during the forecast period, accounting for over 45.8% of the market share in 2026. The growth of the market in North America is due to high awareness about ED, easy availability, and access to ED drugs, and presence of major players in the region. The Europe market is expected to be the second-largest market for sildenafil drug market, accounting for over 25% of the market share in 2026.
The growth of the market in Europe is due to growing geriatric population, increasing prevalence of chronic diseases, and launches of new generic ED drugs. The Asia Pacific market is expected to be the fastest-growing market for sildenafil drug market, with a CAGR of over 9% during the forecast period. The growth of the market in Asia Pacific is due to expanding patient population, rising healthcare expenditure, and growth in online sales of ED drugs. Sildenafil Drug Market Share (%), By Region, 2026 To learn more about this report, Request Free Sample The sildenafil drug market has shown strong growth over the past few years driven by increasing prevalence of erectile dysfunction among men across various age groups. Rising awareness about treatment options and availability of generic versions have also propelled market expansion. generics: The patent expiry of branded sildenafil drugs
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra | 100mg | 12 Pills | 55.64€ 52.99€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Viagra Generic | 200mg | 10 Pills | 40.96€ 39.01€ | |
| Kamagra Soft Tabs | 100mg | 32 Pills | 120.11€ 114.39€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Viagra Generic | 50mg | 30 + 4 Pills | 54.26€ 51.68€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Kamagra Oral Jelly | 100mg | 21 Sachets | 95.92€ 91.35€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Kamagra Oral Jelly | 100mg | 30 + 5 Sachets | 136.20€ 129.71€ |
such as Viagra has led to the launch of generic versions by many pharmaceutical companies.
Increasing prevalence of erectile dysfunction: The prevalence of erectile dysfunction (ED) has been steadily rising across the globe. According to data provided by Cleveland Clinic Foundation, a non-profit academic medical center, around 30-41% of men suffer from ED by the age of 40. The increasing geriatric population and age-related health issues are contributing to the growing patient pool. The high unmet needs of ED patients are expected to drive the demand for sildenafil drugs in the near future. With improving awareness and acceptance for ED treatment, the adoption of sildenafil is likely to increase among patients. The low cost of generics compared
to branded equivalents is boosting their adoption.
However, social stigma continues to restrict many patients from openly seeking medical help, proving a growth barrier. Additionally, availability of alternative treatment modes like penile implants and counseling pose competition. North America currently reigns as the dominant region in the sildenafil market owing to growing adoption rates and reduced price points following introduction of generics. Presence of major pharmaceutical manufacturers as well as high 20mg sildenafil medical awareness among patients have further strengthened its position. Meanwhile, Asia Pacific is expected to emerge as the most lucrative territory over the coming years.
This can be attributed to improving access to healthcare in countries like China and India coupled with rising standards of living. While lifestyle diseases continue pushing diagnostic volumes, favorable regulations supporting generic accessibility can further drive volume growth. In addition, emphasis on erectile dysfunction management during primary check-ups presents an opportunity to educate patients and eliminate hesitation. However, maintaining brand loyalty with flagship products amid intense price wars poses a challenge. Overall, advancements in medical technology along with growing focus on sexual wellness are likely to augment sales in global sildenafil market. Companies are focused on developing generic
The segmented regression for different policy changes (for example, sildenafil patent expiry in June 2013, tadalafil patent expiry in November 2017, and reclassification of sildenafil from prescription medicine to pharmacy medicine in March 2018) could not be performed owing to: a) absence of monthly prescribing and spending data (access was restricted to annual level for historical data prior to 2015); and b) inadequate time-points before and after different policy changes needed to conduct segmented regression analysis.17 There is a lack of literature on the prescribing and management of ED in primary care. Previous studies have reported that many men do not seek help with sexual problems to avoid perceived embarrassment for themselves and their doctors.18,19 The observed increasing trend in the rate of prescriptions may have been contributed by various factors. These include inclusion of ED assessment for men with diabetes in the Quality and Outcomes Framework (QOF) since 2013–2014.20 The QOF required opportunistic screening, advice and assessment of contributory factors, and treatment options for ED in patients with diabetes in primary care. In addition, media, including social media, may have contributed to increased knowledge and awareness of the condition among members of the general public given the licensing of newer PDE-5Is in recent years. The study shows that the introduction of generic versions of both sildenafil in 2013 and tadalafil in 2017 reduced overall spending on drugs used for ED.
The expiry of the patent on sildenafil in June 2013 allowed the NHS to purchase generic sildenafil from other pharmaceutical companies for a competitive price, subsequently reducing the price per item from £31.31 in 2012 to £2.53 in 2014.11 This also allowed sildenafil to be removed from the Selected List Scheme, which restricted prescriptions of certain drugs in May 2014, allowing more men access to the medicine on the NHS, which potentially increased the number of items prescribed.21 The patent on tadalafil also expired in November 2017, leading to a 49% decrease in cost per item from £49.40 in 2017 to £25.12 in 2018. The data suggest that more men are seeking help or being assessed for ED in primary care. The increased presentations and, hence, prescribing for EDs allows further opportunities to screen for the associated risk factors for ED. These include: CVDs such as hypertension, coronary artery disease, peripheral vasculopathy; endocrine disorders such as diabetes, metabolic syndrome, and hyperthyroidisim; as well as assessment of psychogenic risk factors and medication-induced ED.2 Prescribers should be aware of the wider organic, psychogenic nature and linked risk factors of ED including diabetes, vascular disorders, and mental health conditions. The cause of ED needs to be established before treatment can commence and patients should be referred to specialist clinics where appropriate. sildenafil formulations to capture the market share.
Reclassification of sildenafil to pharmacy medicine had a modest impact on prescribing practices. This study was funded by the University of Birmingham. This study represents secondary analysis of the information retrieved from publicly available anonymised datasets and does not warrant formal ethical approval. The authors declare that no competing interests exist. This article is Open Access: CC BY license ( Sildenafil Drug Market is estimated to be valued at USD 3.53 Bn in 2026 and is expected to reach USD 5.63 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that buy pills sildenafil is used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It helps improve blood flow to the penis to achieve and maintain an erection, thus making it an effective treatment for impotence. The key drivers of the sildenafil drug market include the rising prevalence of ED, growing geriatric population, increasing awareness about ED treatment options, and high risk factors like obesity, diabetes, and smoking. The sildenafil drug market is segmented into drug type, indication, distribution channel, dosage form, and region. By drug type, the market is segmented into branded drugs, generics, and over-the-counter (OTC) drugs. The availability of generics has made ED treatment more accessible
Guidelines recommend that a physical examination, including genitourinary, endocrine, vascular, and neurological systems, is undertaken. This can reveal any unsuspected diagnoses, such as Peyronie’s disease, pre-malignant or malignant genital lesions, prostatic enlargement or irregularity or nodularity, or signs and symptoms suggesting hypogonadism.2,3 It is, however, unclear how often patients are screened for the red-flag symptoms. Long-term safety outcomes of PDE-5Is are not understood. Prescribers should, therefore, reassess the continuous use of these drugs on a periodic basis.22,23 Reclassification to allow ‘pharmacy-only’ supply of drugs to free-up GP time and resources have faced successes and barriers in the past.24–26 For example, reclassification of drugs such as chloramphenicol eye products, mild steroids, and antifungal products have been positively received by patients, GPs, and pharmacists. However, reclassified pharmacy version of simvastatin was not adopted in practice to the same extent.24 Research on community pharmacist and patient perspectives on the need, supply, and aspects of risk assessments and referrals are warranted.
GPs and patient experiences of access to sildenafil from pharmacy also need to be further explored. Results of this study suggest that more men are being screened for, or seeking help with, ED. The two-fold observed increase in the population adjusted rate of prescriptions over the past 10 years is less likely to be accounted for by other factors. Promotion of sildenafil by pharmaceutical industries since being made available over the counter for pharmacy sales could have raised awareness of ED among the general public. Higher rate of prescribing in deprived regions offers opportunity for monitoring of linked health conditions such as CVD and diabetes. and affordable, thereby driving the
| Treatment | Average Cost per Month (€) | Effectiveness Rating | Accessibility |
|---|---|---|---|
| Sildenafil | 30 | 8/10 | High |
| Tadalafil | 35 | 8.5/10 | Moderate |
| Vardenafil | 28 | 7.5/10 | Moderate |
| Lifestyle Changes | 0 (free) | Varies | High |
growth of the sildenafil drug market.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités